Hcv: The Journey from Discovery to a Cure: Volume II

NS5A as a target for HCV Drug Discovery.- The Discovery and Development of Daclatasvir: An Inhibitor of the Hepatitis C Virus NS5A Replication Complex.- The Discovery of Ledipasvir (GS-5885): The Potent Once-Daily Oral HCV NS5A Inhibitor in the Single-Tablet Regimen Harvoni(R).- The Discovery of Velpatasvir (GS-5816): The Potent Pan-Genotypic Once-Daily Oral HCV NS5A Inhibitor in the Single-Tablet Regimens Epclusa(R) and Vosevi(R).- Discovery of Elbasvir.- HCV NS5A as an Antiviral Therapeutic Target: From Validation to the Discovery and Development of Ombitasvir and Pibrentasvir as Components of IFN-Sparing HCV Curative Treatments.- Evolution of HCV NS4B Inhibitors.- The Evolution of Clinical Trials for Hepatitis C.- The Clinical Development of Ledipasvir/Sofosbuvir (LDV/SOF, Harvoni(R)).- The Clinical Development of Sofosbuvir/Velpatasvir (SOF/VEL, Epclusa(R)).- The Clinical Development of Sofosbuvir/Velpatasvir/Voxilaprevir (SOF/VEL/VOX, Vosevi(R)).- Clinical Development of Viekira Pak to Mavyret.- Development of ZEPATIER(R).- Real world effectiveness of DAA therapies.- The Benefit of Direct-Acting Antiviral HCV Cure Therapies.- Cure and Control: What Will It Take to Eliminate HCV?.- Perspectives on HCV Cure.